Corpay Free cash flow decreased by 114.2% to -$107.71M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 9.4%, from -$118.92M to -$107.71M. Over 3 years (FY 2021 to FY 2024), Free cash flow shows an upward trend with a 17.6% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $252.35M | $214.41M | $560.45M | -$143.64M | $118.86M | $355.75M | $272.39M | $840.93M | $179.11M | $247.43M | $679.84M | $308.99M | $496.83M | $355.01M | $604.56M | -$118.92M | $1.09B | $760.30M | -$107.71M |
| QoQ Change | — | -15.0% | +161.4% | -125.6% | +182.8% | +199.3% | -23.4% | +208.7% | -78.7% | +38.1% | +174.8% | -54.5% | +60.8% | -28.5% | +70.3% | -119.7% | >999% | -30.1% | -114.2% |
| YoY Change | — | — | — | — | -52.9% | +65.9% | -51.4% | +685.4% | +50.7% | -30.4% | +149.6% | -63.3% | +177.4% | +43.5% | -11.1% | -138.5% | +118.9% | +25.8% | +9.4% |